Akums Drugs and Pharmaceutical, a Delhi-based company, reported a 16% rise in profits compared to the same period last year. The company achieved this through improved operational efficiency. However, revenue decreased by 11.9% due to lower prices of active pharmaceutical ingredients and fluctuating demand.
from Stocks-Markets-Economic Times https://ift.tt/h1zMw3v
Home »
Stocks-Markets-Economic Times
» Akums Drugs adj. net profit rises 16% YoY to Rs 66.7 crore in Q2FY25
Akums Drugs adj. net profit rises 16% YoY to Rs 66.7 crore in Q2FY25
Related Posts:
HDFC to raise up to Rs 10,000 crore next weekThe country's largest mortgage lender said that it will issue secured redeemable non-convertible debentures (NCDs) on private placement basis with an issue size of Rs 2,000 crore and option to retain over-subscription of up t… Read More
Trade Setup: Short-covering led rally likely if Nifty holds 17,000 levelWe enter the penultimate day of expiry of the weekly options and the options data show 17,000 continuing to hold maximum Put Open Interest. This means that if Nifty opens above 17,000 and stays above this level, there are fai… Read More
Ahead of Market: 12 things that will decide stock action on WednesdayMazhar Mohammad of Chartviewindia.in said unless the Nifty50 manages a sustainable close above 17,000 level, the index can breach the recent corrective swing low of 16,782 levels. from Stocks-Markets-Economic Times https://i… Read More
Investment via P-notes hit 43-month high in OctAccording to Securities and Exchange Board of India data, the value of P-note investments in Indian markets -- equity, debt, and hybrid securities -- was at Rs 1,02,553 crore by October end. from Stocks-Markets-Economic Time… Read More
Fed's Jerome Powell weighs earlier end to bond tapering amid hot inflationIt’s “appropriate in my view to consider wrapping up the taper of our asset purchases, which we actually announced at the November meeting, perhaps a few months sooner,” Powell said. from Stocks-Markets-Economic Times https:… Read More
0 Comments:
Post a Comment